Landscapes / Companies

Ionis Pharmaceuticals, Inc. not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
4 approved
2 in Phase 3
Next date
Donidalorsen, Phase 3 trial completes
Drugs
13
in active trials · 39 in all
Trials
19 active
76 since 2021

Drugs13

DrugHow it worksPartnerStageNext dateDetails
—
Approved Dec 2026Phase 3 trial completes
APOC-III-directed RNA Interaction; antisense oligonucleotide
Approved Mar 2027Phase 3 trial completes
Transthyretin-directed RNA Interaction; antisense oligonucleotide
AstraZeneca
Approved 6 Feb 2029Phase 2 trial completes
—
Approved —
—
Phase 3 Aug 2027Phase 3 trial completes
—
Phase 3 —
—
Kardigan
Phase 2 Dec 2026Phase 2 trial completes
—
Phase 1/2 Apr 2027Phase 1/2 trial completes
—
Phase 1/2 Sep 2027Phase 1/2 trial completes
—
Phase 2 Sep 2027Phase 2 trial completes
—
Phase 1/2 Dec 2030Phase 1/2 trial completes
—
Phase 1 Sep 2027Phase 1 trial completes
—
Phase 1 Jun 2028Phase 1 trial completes

About

No active trial
26 other drugs
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Ionis Pharmaceuticals, Inc.

Following is part of Solo: you see every change to Ionis Pharmaceuticals, Inc. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in